WO2010062776A2 - Chimeric dna polymerases - Google Patents
Chimeric dna polymerases Download PDFInfo
- Publication number
- WO2010062776A2 WO2010062776A2 PCT/US2009/063166 US2009063166W WO2010062776A2 WO 2010062776 A2 WO2010062776 A2 WO 2010062776A2 US 2009063166 W US2009063166 W US 2009063166W WO 2010062776 A2 WO2010062776 A2 WO 2010062776A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polymerase
- amino acid
- chimeric
- dna
- domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1252—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
Definitions
- DNA polymerases are enzymes that use single-stranded DNA as a template to synthesize the complementary DNA strand.
- DNA polymerases can add free nucleotides to the 3' end of a newly- forming strand resulting in elongation of the new strand in a 5 '-3' direction.
- Some DNA polymerases can correct mistakes in newly-synthesized DNA. This process is known as error correction.
- These polymerases can recognize an incorrectly incorporated nucleotide and the 3'->5' exonuclease activity of the enzyme allows the incorrect nucleotide to be excised (this activity is known as proofreading).
- the present invention encompasses the discovery that domain swapping can combine desired functional characteristics (e.g., high processivity, high elongation rate, thermostability, resistance to salt, PCR additives (e.g., PCR enhancers) and other impurities, and high fidelity) of different DNA polymerases in a chimeric enzyme.
- desired functional characteristics e.g., high processivity, high elongation rate, thermostability, resistance to salt, PCR additives (e.g., PCR enhancers) and other impurities, and high fidelity
- desired functional characteristics e.g., high processivity, high elongation rate, thermostability, resistance to salt, PCR additives (e.g., PCR enhancers) and other impurities, and high fidelity
- the present invention provides chimeric polymerases containing a first domain having a sequence at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical to an amino acid sequence found in a first DNA polymerase characterized with high processivity, elongation rate, salt resistance, thermostability or TMAC tolerance; and a second domain having a sequence at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical to an amino acid sequence found in a second DNA polymerase characterized with high fidelity, wherein the chimeric polymerases are characterized with both high fidelity and high processivity, elongation rate, or salt resistance.
- a first domain having a sequence at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%
- high processivity refers to a processivity higher than 20nts (e.g., higher than 40nts, 60nts, 80nts, lOOnts, 120nts, 140nts, 160nts, 180nts, 200nts, 220nts, 240nts, 260nts,280nts, 300nts, 320nts, 340nts, 360nts, 380nts, 400nts, or higher) per association/disassociation with the template.
- 20nts e.g., higher than 40nts, 60nts, 80nts, lOOnts, 120nts, 140nts, 160nts, 180nts, 200nts, 220nts, 240nts, 260nts,280nts, 300nts, 320nts, 340nts, 360nts, 380nts, 400n
- high elongation rate refers to an elongation rate higher than 25 nt/s (e.g., higher than 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140 nt/s).
- high salt resistance refers to the ability of a DNA polymerase to substantially maintain its enzymatic activity at a salt concentration higher than 30 mM (e.g., higher than 35 mM, 4OmM, 45mM, or 5OmM).
- high fidelity refers to an error rate less than 4.45 X 10 "6 (e.g., less than 4.0 X 10 "6 , 3.5 X 10 "6 , 3.0 X 10 "6 , 2.5 X 10 "6 , 2.0 X 10 “6 , 1.5 X 10 "6 , 1.0 X 10 "6 , 0.5 X 10 “6 ) mutations/nt/doubling.
- the term “high TMAC tolerance” refers to the ability of a DNA polymerase to substantially maintain its enzymatic activity at a TMAC (tetra- methyl ammonium chloride) concentration higher than 10 mM (e.g., higher than 15 mM, 20 mM, 25 mM, 30 mM).
- the term “high thermostability” refers to the ability of a DNA polymerase to substantially maintain its enzymatic activity after more than 30 minutes incubation at 98 0 C (e.g., 45 min, 60 min, 90min, 180 min, 210 min, 240 min).
- the terms of "processivity,” “elongation rate,” “fidelity,” “salt resistance,” “TMAC tolerance,” and “thermostability” are further defined in the Definitions section.
- exemplary first DNA polymerases suitable for the present invention include, but are not limited to, KOD polymerase, TNAl polymerase, Thermococcus sp. 9 degrees N-7, T4, T7, or phi29.
- the first DNA polymerase is KOD polymerase.
- exemplary second DNA polymerases suitable for the invention include, but are not limited to, polymerases isolated from Pyrococcus furiosus, P. abyssi, T. gorgonarius, T. litoralis, T. zilligii, T. sp. GT, or P. sp. GB-D.
- the second DNA polymerase is Pfu polymerase.
- the first DNA polymerase is KOD polymerase and the second DNA polymerase is Pfu polymerase.
- suitable first domain is an exonuclease domain, N- terminal domain, and/or a thumb domain.
- suitable second domain is palm and/or fingers domain.
- amino acid sequences found in the first DNA polymerase correspond to amino acid residues 26 to 105 of KOD polymerase (SEQ ID NO:11), amino acid residues 156 to 301 of KOD polymerase (SEQ ID NO:11), and/or amino acid residues 612 to 749 of KOD polymerase (SEQ ID NO: 11).
- amino acid sequences found in the second DNA polymerase correspond to amino acid residues 394 to 563 of Pfu polymerase (SEQ ID NO: 9).
- a chimeric polymerase in accordance with the present invention include a first domain having a consensus sequence selected from the group consisting of
- chimeric polymerase is characterized with high fidelity and high processivity, elongation rate, salt resistance, TMAC or other PCR enhancer tolerance or thermostability.
- chimeric polymerases in accordance with the present invention are defined by consensus sequence
- chimeric polymerases in accordance with the present invention are defined by consensus sequence
- XGT (SEQ ID NO:39), wherein X is any amino acid or a peptide bond.
- the present invention further provides chimeric polymerases containing a first domain having a sequence at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical to an amino acid sequence found in an exonuclease domain, an N-terminal domain, and/or a thumb domain of a first DNA polymerase; and a second domain having a sequence at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical to an amino acid sequence found in palm and/or fingers domain of a second DNA polymerase.
- a first domain having a sequence at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical to an amino acid sequence found in palm and/or fingers domain of a
- the chimeric polymerase has a fidelity higher than that of the second DNA polymerase and a processivity, an elongation rate, a salt resistance, a TMAC or other PCR enhancer tolerance or a thermostability higher than that of the first DNA polymerase.
- the present invention provides methods of engineering chimeric polymerases.
- inventive methods in accordance with the present invention include steps of: (a) providing an N-terminal domain, an exonuclease domain, and/or a thumb domain based on a first DNA polymerase; (b) providing a palm and/or fingers domain based on a second DNA polymerase; (c) combining the domains from step (a) and step (b) to form a chimeric polymerase; wherein the chimeric polymerase has a fidelity higher than that of the first DNA polymerase and a processivity, an elongation rate, a salt resistance, a TMAC or other PCR enhancer tolerance or a thermostability higher than that of the second DNA polymerase.
- a chimeric polymerase engineered according to the present invention has a processivity, an elongation rate, a salt resistance, a TMAC or other PCR enhancer tolerance or a thermostability substantially similar to that of the first DNA polymerase and a fidelity substantially similar to that of the second DNA polymerase.
- exemplary first DNA polymerases suitable for the present invention include, but are not limited to, KOD polymerase, TNAl polymerase, Thermococcus sp. 9 degrees N-7, T4, T7, or phi29.
- the first DNA polymerase is KOD polymerase.
- exemplary second DNA polymerases suitable for the invention include, but are not limited to, polymerases isolated from Pyrococcus furiosus, P. abyssi, T. gorgonarius, T. litoralis, T. zilligii, T. sp. GT, or P. sp. GB-D.
- the second DNA polymerase is Pfu polymerase.
- the first DNA polymerase is KOD polymerase and the second DNA polymerase is Pfu polymerase. In some embodiments, the first DNA polymerase is Pfu polymerase and the second DNA polymerase is KOD polymerase.
- the present invention provides methods of improving the fidelity of a DNA polymerase.
- inventive methods in accordance with the invention include a step of replacing a sequence within the palm and/or fingers domain of the DNA polymerase of interest with a corresponding sequence from a different DNA polymerase that is characterized with higher fidelity relative to the DNA polymerase of interest.
- the present invention provides methods of improving the processivity, elongation rate, salt resistance, TMAC or other PCR enhancer tolerance or thermostability of a DNA polymerase.
- inventive methods in accordance with the present invention include a step of replacing a sequence within the N- terminal domain, the exonuclease domain and/or the thumb domain of the DNA polymerase of interest with a corresponding sequence from a different DNA polymerase that is characterized with higher processivity, elongation rate, salt resistance, TMAC or other PCR enhancer tolerance or thermostability relative to the DNA polymerase of interest.
- chimeric polymerases in accordance with the present invention contain an amino acid sequence at least 80% identical to SEQ ID NO: 16 (the Kofu amino acid sequence as shown in the Sequences section).
- a chimeric polymerase in accordance with the present invention contains the amino acid sequence of SEQ ID NO: 16.
- chimeric polymerases in accordance with the present invention contain an amino acid sequence at least 80% identical to SEQ ID NO: 15 (the Pod amino acid sequence as shown in the Sequences section).
- a chimeric polymerase in accordance with the present invention contains the amino acid sequence of SEQ ID NO: 15.
- the present invention also provides kits and compositions containing various chimeric polymerases described herein and uses thereof (e.g., methods of amplifying DNA fragments using chimeric DNA polymerases of the invention).
- the present invention provides nucleotide sequences encoding various chimeric polymerases described herein and vectors and/or cells containing the nucleotide sequences according to the invention.
- Figure 1 depicts an alignment of domains in exemplary naturally-occurring type B DNA polymerases and exemplary chimeric DNA polymerases, Kofu and Pod.
- the KOD and Pfu polymerase domains that were swapped in the Kofu and Pod chimeras are indicated above the alignment.
- Figure 2 depicts that an exemplary chimeric polymerase Pod contains the N- terminal domain, the 3 '-5' exonuc lease domain and the thumb domain of Pfu and the palm and fingers domain of KOD and the reciprocal chimeric polymerase Kofu contains the N- terminal domain, the 3 '-5' exonuclease domain and the thumb domain of KOD and the palm and fingers domain of Pfu.
- Figure 3 depicts exemplary results showing the thermostability of KOD, Pfu,
- Figure 4 depicts exemplary results showing the salt resistance of KOD, Pfu,
- FIG. 5 depicts exemplary results showing the TMAC tolerance of KOD, Pfu,
- amino acid in its broadest sense, refers to any compound and/or substance that can be incorporated into a polypeptide chain.
- an amino acid has the general structure H 2 N-C(H)(R)-COOH.
- an amino acid is a naturally-occurring amino acid.
- an amino acid is a synthetic amino acid; in some embodiments, an amino acid is a D-amino acid; in some embodiments, an amino acid is an L-amino acid.
- Standard amino acid refers to any of the twenty standard L-amino acids commonly found in naturally occurring peptides.
- Nonstandard amino acid refers to any amino acid, other than the standard amino acids, regardless of whether it is prepared synthetically or obtained from a natural source.
- synthetic amino acid encompasses chemically modified amino acids, including but not limited to salts, amino acid derivatives (such as amides), and/or substitutions.
- Amino acids including carboxy- and/or amino-terminal amino acids in peptides, can be modified by methylation, amidation, acetylation, and/or substitution with other chemical groups. Amino acids may participate in a disulfide bond.
- amino acid is used interchangeably with “amino acid residue,” and may refer to a free amino acid and/or to an amino acid residue of a peptide. It will be apparent from the context in which the term is used whether it refers to a free amino acid or a residue of a peptide. It should be noted that all amino acid residue sequences are represented herein by formulae whose left and right orientation is in the conventional direction of amino-terminus to carboxy-terminus.
- Base Pair As used herein, base pair refers to a partnership of adenine (A) with thymine (T), or of cytosine (C) with guanine (G) in a double stranded DNA molecule.
- Chimeric polymerase As used herein, the term “chimeric polymerase” (also referred to as “chimera”) refers to any polymerase containing two or more heterologous domains, amino acid sequences, peptides, and/or proteins joined either covalently or non- covalently to produce a polymerase that does not occur in nature.
- a chimeric polymerase contains a first domain joined to a second domain, wherein the first and second domains are not found in the same relationship in nature.
- the first domain is derived from a first DNA polymerase and a second domain is derived from a second DNA polymerase.
- the first and second DNA polymerases are characterized with at least one distinct functional characteristics (e.g., processivity, elongation rate, fidelity, salt tolerance, tolerance to PCR additives or thermostability).
- a sequence derived from a DNA polymerase of interest refers to any sequence found in the DNA polymerase of interest, or any sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical to an amino acid sequence found in the DNA polymerase of interest.
- a "chimeric polymerase” according to the invention may contain two or more amino acid sequences from related or similar polymerases (e.g., proteins sharing similar sequences and/or structures), joined to form a new functional protein.
- a “chimeric polymerase” according to the invention may contain two or more amino acid sequences from unrelated polymerases, joined to form a new functional protein.
- a chimeric polymerase of the invention may be an "interspecies” or “intergenic” fusion of protein structures expressed by different kinds of organisms.
- Complementary refers to the broad concept of sequence complementarity between regions of two polynucleotide strands or between two nucleotides through base-pairing. It is known that an adenine nucleotide is capable of forming specific hydrogen bonds ("base pairing") with a nucleotide which is thymine or uracil. Similarly, it is known that a cytosine nucleotide is capable of base pairing with a guanine nucleotide.
- DNA binding affinity typically refers to the activity of a DNA polymerase in binding DNA nucleic acid.
- DNA binding activity can be measured in a two band-shift assay.
- double-stranded nucleic acid the 452-bp Hindlll-EcoRV fragment from the S. solfataricus lacS gene
- a specific activity of at least about 2.5 X lO 7 cpm/ ⁇ g or at least about 4000 cpm/fmol
- a reaction mixture is prepared containing at least about 0.5 ⁇ g of the polypeptide in about 10 ⁇ l of binding buffer (50 mM sodium phosphate buffer (pH 8.0), 10% glycerol, 25 mM KCl, 25 mM MgCl 2 ). The reaction mixture is heated to 37 0 C. for 10 min.
- binding buffer 50 mM sodium phosphate buffer (pH 8.0), 10% glycerol, 25 mM KCl, 25 mM MgCl 2 .
- nucleic acid binding activity may be quantified using standard densitometric methods to measure the amount of radioactivity in the binding complex relative to the total amount of radioactivity in the initial reaction mixture.
- Other methods of measuring DNA binding affinity are known in the art (see, e.g., Kong et al. (1993) J. Biol. Chem. 268(3): 1965-1975).
- Domain refers to an amino acid sequence of a polypeptide (e.g. , polymerase) comprising one or more defined functions or properties.
- Elongation rate refers to the average speed at which a DNA polymerase extends a polymer chain.
- a high elongation rate refers to an elongation rate higher than 25 nt/s (e.g., higher than 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140 nt/s).
- Enzyme activity refers to the specificity and efficiency of a DNA polymerase. Enzyme activity of a DNA polymerase is also referred to as "polymerase activity,” which typically refers to the activity of a DNA polymerase in catalyzing the template-directed synthesis of a polynucleotide. Enzyme activity of a polymerase can be measured using various techniques and methods known in the art. For example, serial dilutions of polymerase can be prepared in dilution buffer (e.g., 20 mM Tris.Cl, pH 8.0, 50 mM KCl, 0.5% NP 40, and 0.5% Tween-20).
- dilution buffer e.g., 20 mM Tris.Cl, pH 8.0, 50 mM KCl, 0.5% NP 40, and 0.5% Tween-20.
- reaction mixtures For each dilution, 5 ⁇ l can be removed and added to 45 ⁇ l of a reaction mixture containing 25 mM TAPS (pH 9.25), 50 mM KCl, 2 niM MgC12, 0.2 mM dATP, 0.2 niM dGTP, 0.2 mM dTTP, 0.1 niM dCTP, 12.5 ⁇ g activated DNA, 100 ⁇ M [ ⁇ - 32 P]dCTP (0.05 ⁇ Ci/nmol) and sterile deionized water.
- the reaction mixtures can be incubated at 37 0 C. (or 74 0 C.
- thermostable DNA polymerases for 10 minutes and then stopped by immediately cooling the reaction to 4 0 C and adding 10 ⁇ l of ice-cold 60 mM EDTA. A 25 ⁇ l aliquot can be removed from each reaction mixture. Unincorporated radioactively labeled dCTP can be removed from each aliquot by gel filtration (Centri-Sep, Princeton Separations, Adelphia, N. J.). The column eluate can be mixed with scintillation fluid (1 ml). Radioactivity in the column eluate is quantified with a scintillation counter to determine the amount of product synthesized by the polymerase.
- One unit of polymerase activity can be defined as the amount of polymerase necessary to synthesize 10 nmole of product in 30 minutes (Lawyer et al. (1989) J. Biol. Chem. 264:6427-647). Other methods of measuring polymerase activity are known in the art (see, e.g., Sambrook et al. (2001) Molecular Cloning: A Laboratory Manual (3 rd ed., Cold Spring Harbor Laboratory Press, NY)).
- fidelity refers to the accuracy of DNA polymerization by template-dependent DNA polymerase.
- the fidelity of a DNA polymerase is typically measured by the error rate (the frequency of incorporating an inaccurate nucleotide, i.e., a nucleotide that is not complementary to the template nucleotide).
- the accuracy or fidelity of DNA polymerization is maintained by both the polymerase activity and the 3'-5' exonuclease activity of a DNA polymerase.
- high fidelity refers to an error rate less than 4.45 X 10 "6 (e.g., less than 4.0 X 10 "6 , 3.5 X 10 "6 , 3.0 X 10 "6 , 2.5 X 10 "6 , 2.0 X 10 "6 , 1.5 X 10 "6 , 1.0 X 10 "6 , 0.5 X 10 "6 ) mutations/nt/doubling.
- the fidelity or error rate of a DNA polymerase may be measured using assays known to the art. For example, the error rates of DNA polymerases can be tested using the lad PCR fidelity assay described in Cline, J. et al. (1996) NAR 24: 3546-3551.
- a 1.9 kb fragment encoding the lacIOlacZa target gene is amplified from pPRIAZ plasmid DNA using 2.5U DNA polymerase (i.e., amount of enzyme necessary to incorporate 25 nmoles of total dNTPs in 30 min. at 72°C) in the appropriate PCR buffer.
- the / ⁇ c/-containing PCR products are then cloned into lambda GTlO arms, and the percentage of / ⁇ c/ mutants (MF, mutation frequency) is determined in a color screening assay, as described (Lundberg, K. S. , Shoemaker, D. D. , Adams, M. W. W. , Short, J. M. , Sorge, J. A., and Mathur, E.
- Error rates are expressed as mutation frequency per bp per duplication (MF/bp/d), where bp is the number of detectable sites in the lad gene sequence (349) and d is the number of effective target doublings.
- MF/bp/d mutation frequency per bp per duplication
- bp is the number of detectable sites in the lad gene sequence (349)
- d is the number of effective target doublings.
- any plasmid containing the lacIOlacZa target gene can be used as template for the PCR.
- the PCR product may be cloned into a vector different from lambda GT (e.g., plasmid) that allows for blue/white color screening.
- joined refers to any method known in the art for functionally connecting polypeptide domains, including without limitation recombinant fusion with or without intervening domains, inter-mediated fusion, non-covalent association, and covalent bonding, including disulfide bonding, hydrogen bonding, electrostatic bonding, and conformational bonding.
- Nucleotide As used herein, a monomeric unit of DNA or RNA consisting of a sugar moiety (pentose), a phosphate, and a nitrogenous heterocyclic base. The base is linked to the sugar moiety via the glycosidic carbon (1 ' carbon of the pentose) and that combination of base and sugar is a nucleoside. When the nucleoside contains a phosphate group bonded to the 3' or 5' position of the pentose it is referred to as a nucleotide.
- a sequence of operatively linked nucleotides is typically referred to herein as a "base sequence” or “nucleotide sequence,” and is represented herein by a formula whose left to right orientation is in the conventional direction of 5 '-terminus to 3 '-terminus.
- Oligonucleotide or Polynucleotide As used herein, the term
- oligonucleotide is defined as a molecule including two or more deoxyribonucleotides and/or ribonucleotides, preferably more than three. Its exact size will depend on many factors, which in turn depend on the ultimate function or use of the oligonucleotide.
- the oligonucleotide may be derived synthetically or by cloning.
- polynucleotide refers to a polymer molecule composed of nucleotide monomers covalently bonded in a chain.
- DNA deoxyribonucleic acid
- RNA ribonucleic acid
- Polymerase As used herein, a "polymerase” refers to an enzyme that catalyzes the polymerization of nucleotide (i.e., the polymerase activity). Generally, the enzyme will initiate synthesis at the 3'- end of the primer annealed to a polynucleotide template sequence, and will proceed towards the 5' end of the template strand.
- a "DNA polymerase” catalyzes the polymerization of deoxynucleotides.
- Processivity refers to the ability of a polymerase to remain attached to the template and perform multiple modification reactions. “Modification reactions” include but are not limited to polymerization, and exonucleolytic cleavage. In some embodiments, “processivity” refers to the ability of a DNA polymerase to perform a sequence of polymerization steps without intervening dissociation of the enzyme from the growing DNA chains. Typically, “processivity” of a DNA polymerase is measured by the length of nucleotides (for example 20 nts, 300 nts, 0.5-1 kb, or more) that are polymerized or modified without intervening dissociation of the DNA polymerase from the growing DNA chain.
- Processivity can depend on the nature of the polymerase, the sequence of a DNA template, and reaction conditions, for example, salt concentration, temperature or the presence of specific proteins.
- high processivity refers to a processivity higher than 20nts (e.g., higher than 40nts, 60nts, 80nts, lOOnts, 120nts, 140nts, 160nts, 180nts, 200nts, 220nts, 240nts, 260nts,280nts, 300nts, 320nts, 340nts, 360nts, 380nts, 400nts, or higher) per association/disassociation with the template.
- Processivity can be measured according the methods defined herein and in WO 01/92501 Al.
- Primer refers to an oligonucleotide, whether occurring naturally or produced synthetically, which is capable of acting as a point of initiation of nucleic acid synthesis when placed under conditions in which synthesis of a primer extension product which is complementary to a nucleic acid strand is induced, e.g. , in the presence of four different nucleotide triphosphates and thermostable enzyme in an appropriate buffer ("buffer” includes appropriate pH, ionic strength, cofactors, etc.) and at a suitable temperature.
- buffer includes appropriate pH, ionic strength, cofactors, etc.
- the primer is first treated to separate its strands before being used to prepare extension products.
- the primer is an oligodeoxyribonucleotide.
- the primer must be sufficiently long to prime the synthesis of extension products in the presence of the thermostable enzyme. The exact lengths of the primers will depend on many factors, including temperature, source of primer and use of the method. For example, depending on the complexity of the target sequence, the oligonucleotide primer typically contains 15-25 nucleotides, although it may contain more or few nucleotides. Short primer molecules generally require lower temperatures to form sufficiently stable hybrid complexes with template.
- Salt resistance refers to the ability of a DNA polymerase to substantially maintain its enzymatic activity in the presence of salt or PCR additives (e.g., TMAC).
- salt or PCR additives e.g., TMAC
- resistance to salt or PCR additives is measured by the maximum salt concentration at which a DNA polymerase is still active. The maximum salt concentration differs for each polymerase and is known in the art, or can be experimentally determined according to methods in the art. For example, Pfu is inhibited at 30 mM salt (in a PCR reaction).
- Synthesis refers to any in vitro method for making new strand of polynucleotide or elongating existing polynucleotide (i.e., DNA or RNA) in a template dependent manner.
- Synthesis includes amplification, which increases the number of copies of a polynucleotide template sequence with the use of a polymerase.
- Polynucleotide synthesis e.g., amplification
- DNA synthesis includes, but is not limited to, PCR, the labeling of polynucleotide (i.e., for probes and oligonucleotide primers), polynucleotide sequencing.
- Template DNA molecule refers to a strand of a nucleic acid from which a complementary nucleic acid strand is synthesized by a DNA polymerase, for example, in a primer extension reaction.
- Template dependent manner refers to a process that involves the template dependent extension of a primer molecule (e.g., DNA synthesis by DNA polymerase).
- template dependent manner typically refers to polynucleotide synthesis of RNA or DNA wherein the sequence of the newly synthesized strand of polynucleotide is dictated by the well-known rules of complementary base pairing (see, for example, Watson, J. D. et al., In: Molecular Biology of the Gene, 4th Ed. , W. A. Benjamin, Inc., Menlo Park, Calif. (1987)).
- thermostable enzyme refers to an enzyme which is stable to heat (also referred to as heat-resistant) and catalyzes (facilitates) polymerization of nucleotides to form primer extension products that are complementary to a polynucleotide template sequence.
- thermostable stable polymerases are preferred in a thermocycling process wherein double stranded nucleic acids are denatured by exposure to a high temperature (e.g., about 95 C) during the PCR cycle.
- thermostable enzyme described herein effective for a PCR amplification reaction satisfies at least one criteria, i.e., the enzyme do not become irreversibly denatured (inactivated) when subjected to the elevated temperatures for the time necessary to effect denaturation of double- stranded nucleic acids.
- Irreversible denaturation for purposes herein refers to permanent and complete loss of enzymatic activity.
- the heating conditions necessary for denaturation will depend, e.g., on the buffer salt concentration and the length and nucleotide composition of the nucleic acids being denatured, but typically range from about 90 0 C to about 98 0 C for a time depending mainly on the temperature and the nucleic acid length, typically about 0.2 to four minutes.
- thermostable enzymes will not become irreversibly denatured at about 90 0 C -100 0 C.
- a thermostable enzyme suitable for the invention has an optimum temperature at which it functions that is higher than about 40 0 C, which is the temperature below which hybridization of primer to template is promoted, although, depending on (1) magnesium and salt, concentrations and (2) composition and length of primer, hybridization can occur at higher temperature (e.g., 45 0 C - 70 0 C). The higher the temperature optimum for the enzyme, the greater the specificity and/or selectivity of the primer-directed extension process.
- enzymes that are active below 40 0 C are also with the scope of this invention provided they are heat- stable.
- the optimum temperature ranges from about 50 0 C to 90 0 C (e.g., 6O 0 C - 80 0 C).
- TMAC or other PCR enhancer tolerance refers to the ability of a DNA polymerase to substantially maintain its enzymatic activity in the presence of TMAC or other PCR enhancers (e.g., glycerol, DMSO, betaine, amides, other tetramethyl ammonium salts).
- TMAC or other PCR enhancer tolerance also referred to as TMAC or other PCR enhancer resistance
- TMAC or other PCR enhancer tolerance refers to the ability of a DNA polymerase to substantially maintain its enzymatic activity in the presence of TMAC or other PCR enhancers (e.g., glycerol, DMSO, betaine, amides, other tetramethyl ammonium salts).
- the present invention provides, among other things, chimeric DNA polymerases containing heterologous domains having sequences derived from at least two DNA polymerases that have at least one distinct functional characteristics (e.g., elongation rate, processivity, error rate or fidelity, salt tolerance or resistance) and methods of making and using the same.
- chimeric DNA polymerases containing heterologous domains having sequences derived from at least two DNA polymerases that have at least one distinct functional characteristics (e.g., elongation rate, processivity, error rate or fidelity, salt tolerance or resistance) and methods of making and using the same.
- Chimeric DNA polymerases in accordance with the present invention may be engineered from any DNA polymerases, in particular, thermostable polymerases.
- DNA polymerases are grouped into six families: A, B, C, D, X and Y. Families A, B, C are grouped based on their amino acid sequence homologies to E. coli polymerases I, II, and III, respectively. Family X has no homologous E. coli polymerases.
- DNA polymerases suitable for the present invention are family B DNA polymerases.
- Family B polymerases include, but are not limited to, E.
- DNA polymerases suitable for the invention are archaeal polymerases (e.g., euryarchaeal polymerases).
- Suitable exemplary archaeal polymerases include, but are not limited to, DNA polymerases from archaea (e.g., Thermococcus litoralis (VentTM, GenBank: AAA72101), Pyrococcus furiosus (Pfu, GenBank: D12983, BAA02362), Pyrococcus woesii, Pyrococcus GB-D (Deep VentTM, GenBank: AAA67131), Thermococcus kodakaraensis KODI (KOD, GenBank: BD175553, BAA06142; Thermococcus sp.
- DNA polymerases from archaea e.g., Thermococcus litoralis (VentTM, GenBank: AAA72101), Pyrococcus furiosus (Pfu, GenBank: D12983, BAA02362), Pyrococcus woesii, Pyrococcus GB-D (Deep VentTM, Gen
- strain KOD (Pfx, GenBank: AAE68738)), Thermococcus gorgonarius (Tgo, Pdb: 4699806), Sulfolobus solataricus (GenBank: NC002754, P26811), Aeropyrum pernix (GenBank: BAA81109), Archaeglobus fulgidus (GenBank: 029753), Pyrobaculum aerophilum (GenBank: AAL63952), Pyrodictium occultum (GenBank: BAA07579, BAA07580), Thermococcus 9 degree Nm (GenBank: AAA88769, Q56366), Thermococcus fumicolans (GenBank: CAA93738, P74918), Thermococcus hydrothermalis (GenBank: CAC 18555), Thermococcus sp.
- GE8 (GenBank: CAC12850), Thermococcus sp. JDF-3 (GenBank: AX135456; WO0132887), Thermococcus sp. TY (GenBank: CAA73475), Pyrococcus abyssi (GenBank: P77916), Pyrococcus glycovorans (GenBank: CAC 12849), Pyrococcus horikoshii (GenBank: NP 143776), Pyrococcus sp. GE23 (GenBank: CAA90887), Pyrococcus sp.
- Additional representative temperature-stable family A and B polymerases include, e.g., polymerases extracted from the thermophilic bacteria Thermus species (e.g.,flavus, ruber, thermophilus, lacteus, rubens, aquaticus), Bacillus stearothermophilus, Thermotoga maritima, Methanothermus fervidus .
- DNA polymerases suitable for the present invention include DNA polymerases that have not yet been isolated.
- Suitable polymerases for the present invention include fusion polymerases.
- Fusion polymerases generally contain an additional protein domain at the N- or C-terminus that changes the phenotype of the fusion polymerase compared to the polymerase without the extra domain.
- Exemplary polymerases include, but are not limited to, polymerases with double-stranded DNA-binding domains fused at the C- or N-terminus.
- Further examples of fusion polymerases include those with dUTPase fused to the N-or C-terminus (U.S. patent application 20070190538).
- chimeric DNA polymerases according to the invention contain sequences derived from two or more DNA polymerases that have at least one distinct functional characteristic.
- exemplary functional characteristics include, but are not limited to, processivity, elongation rate, fidelity, resistance to salt or PCR additive (e.g., PCR enhancers), thermostability, strand displacement activity, exonuclease activity, uracil read- ahead function, nucleotide selectivity, ability to incorporate modified analogs, and reverse transcriptase activity.
- some DNA polymerases are characterized with high fidelity.
- high fidelity refers to an error rate less than 4.45 X 10 "6 (e.g., less than 4.0 X 10 "6 , 3.5 X 10 "6 , 3.0 X 10 "6 , 2.5 X 10 "6 , 2.0 X 10 "6 , 1.5 X 10 "6 , 1.0 X 10 "6 , 0.5 X 10 ⁇ 6 ) mutations/nt/doubling.
- Some DNA polymerases are characterized with high processivity.
- high processivity refers to a processivity higher than 20nts (e.g., higher than 40nts, 60nts, 80nts, lOOnts, 120nts, 140nts, 160nts, 180nts, 200nts, 220nts, 240nts, 260nts,280nts, 300nts, 320nts, 340nts, 360nts, 380nts, 400nts, or higher) per association/disassociation with the template.
- Some DNA polymerases are characterized with high elongation rate.
- high elongation rate refers to an elongation rate higher than 25 nt/s (e.g., higher than 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140 nt/s).
- Some enzymes are characterized with high resistance to salt (also referred to as salt tolerance).
- high resistance to salt also referred to as high salt tolerance
- high resistance to salt refers to the ability of a DNA polymerase to substantially maintain its activity at a salt concentration higher than 3OmM (e.g., higher than 35mM, 4OmM, 45mM, 5OmM).
- PCR additives are PCR enhancers.
- TMA salts, DMSO, betaine and formamide act as PCR enhancers (Kovarova and Draber. (2000) Nucl. Acids. Res. 28(13), e70).
- glycerol Another example of PCR enhancers.
- Some enzymes are characterized with resistance to PCR enhancers, in particular, TMAC (also referred to as TMAC tolerance).
- the term "high TMAC tolerance” refers to the ability of a DNA polymerase to substantially maintain its enzymatic activity at a TMAC (tetra-methyl ammonium chloride) concentration higher than 10 mM (e.g., higher than 15 mM, 20 mM). Certain characteristics of exemplary DNA polymerases are shown in Table 1.
- enzymes with high salt tolerance are also characterized with high processivity and/or elongation rate.
- salt tolerance affects the binding affinity between polymerase and DNA which, in turn, affects processivity or elongation rate.
- binding of polymerases to DNA involves binding interaction between positively charged amino acid residues and negatively charged DNA.
- competition from the anions of the salt for the positively charged amino acid residues on the polymerases lead to diminished DNA binding affinity. See, Pavlov et al. (2002) Proc. Natl. Acad. Sci. 99(21): 13510-13515, which is incorporated by reference herein.
- increasing the contact points between DNA and polymerase may increase the salt resistance of the polymerase as well as the processivity or elongation rate because the additional contact points between DNA and polymerase may increase binding affinity of the polymerase for DNA and decrease the rate of dissociation so that the polymerase will remain associated with DNA longer, which will in turn lead to an increase in processivity.
- Pavlov et al. added helix-hairpin-helix (HhH) motifs from topoisomerase V to Taq and Pfu. These motifs are involved in DNA binding in topoisomerase V. Pavlov et al. showed that both Pfu and Taq become more salt resistant when fused to the HhH motifs. Pavlov et al.
- dsDNA binding proteins e.g., Sso7d
- Sso7d can be fused to DNA polymerases to increase the number of contact points between DNA and polymerases (Wang et al. (2004) Nucl. Acids Res. 32(3): 1197-1207, which is incorporated by reference herein).
- Sso7d is a sequence non-specific dsDNA binding protein involved in ensuring DNA stability and/or DNA packing in Sulfolobus solfataricus . Fusion of Sso7d to both Taq and Pfu increased the salt resistance and processivity of the polymerases.
- Exemplary DNA polymerases characterized with high processivity, elongation rate, thermostability, salt or PCR enhancer tolerance include, but are not limited to, KOD polymerase, TNAl polymerase, Thermococcus sp. 9 degrees N-7, T4, T7, or phi29.
- Exemplary DNA polymerases characterized with high fidelity include, but are not limited to, polymerases isolated from Pyrococcus furiosus, P. abyssi, T. gorgonarius, T. litoralis, T. zilligii, T. sp. GT, or P. sp. GB-D.
- KOD, Pfu, T. gorgonarius, T. zilligii, T. litoralis and Thermococcus sp. 9N-7 polymerases are used to engineer chimeric DNA polymerases (see the Example sections). Domains of DNA polymerases
- archaeal DNA polymerases include at least the following domains:
- the polymerase activity has been associated with palm, fingers and thumb domains.
- the palm subdomain is thought to be the catalytic site of the polymerase.
- the polymerase catalyzes a phosphoryl transfer reaction in which the alpha phosphate of the incoming dNTP undergoes nucleophilic attack from the OH primer terminus.
- three carboxylate side chains are important to this active site. These residues may bind two metal ions (Mg++) which may facilitate deprotonation of the OH terminus and formation of a transition state at the alpha phosphate of the dNTP.
- the thumb domain is believed to interact with the minor grove of the newly synthesized dsDNA and also with the incoming nucleotide.
- the thumb domain is less conserved but typically has a largely helical structure.
- the fingers domain may play a role in template fixation and nucleotide specificity. Like the thumb domain, it is likely to interact with the incoming nucleotide.
- the thumb domain may contain ⁇ helices, and/or ⁇ strands. It is thought that unbound DNA polymerases form open conformations of the fingers and thumb domains, and when the DNA is bound, the two domains move towards the palm domain to hold the DNA template and primer more tightly and to probe for Watson-Crick base pairing between the incoming nucleotide and the template nucleotide.
- the uracil read-ahead function has been associated with the N-terminal domain.
- archaeal family B DNA polymerases are able to recognize unrepaired uracil in a template strand and stall polymerization upstream of the lesion to prevent an A-T mutation.
- a "pocket" in the N-terminal domains of archaeal DNA polymerases was identified to be positioned to interact with the template strand and provide this uracil read- ahead function (Fogg et al. (2002) Nature Structural Biology 9(12), 922-927).
- the exonuclease domain is associated with either 5'-> 3' exonuclease activity,
- the fidelity is affected by the ratio of the polymerase and the exonuclease activity, which may be influenced by the rate of dissociation, conformational change, and the rate of nucleotide incorporation in the presence of mismatched nucleotides. It has also been suggested that the balance between the 3 ' -> 5 ' exonuclease activity and the polymerase activity is mediated by a flexible loop containing the Y-GG/A motif located between the N-terminal and exonuclease domains and the C-terminal polymerase domains (i.e., the palm, fingers and thumb domains). See, Bohlke et al. (2000) Nucl. Acids Res.
- heterologous domains from different DNA polymerases may be combined to form a chimeric polymerase.
- Suitable domains include naturally-occurring N- terminal domains, exonuclease domains, palm, fingers, and/or thumb domains found in various DNA polymerases.
- Naturally-occurring N-terminal domains, exonuclease domains, palm, fingers, and/or thumb domains in various DNA polymerases are well defined.
- an N-terminal domain may include a sequence corresponding to amino acid residues 26 to 105 of KOD polymerase (SEQ ID NO:11); an exonuclease domain may include a region corresponding to amino acid residues 156 to 301 of KOD polymerase (SEQ ID NO: 11); a thumb domain may include a region corresponding to amino acid residues 612 to 749 of KOD polymerase (SEQ ID NO:11); and palm and fingers domain may include a region corresponding to amino acid residues 394 to 563 of Pfu polymerase (SEQ ID NO: 9).
- Corresponding domains or positions in various DNA polymerases can be determined by alignment of amino acid sequences. Alignment of amino acid sequences can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. Preferably, the WU-BLAST-2 software is used to determine amino acid sequence identity (Altschul et al., Methods in Enzymology 266, 460-480 (1996); http://blast.wustl/edu/blast/README.html).
- WU-BLAST-2 uses several search parameters, most of which are set to the default values.
- HSP score (S) and HSP S2 parameters are dynamic values and are established by the program itself, depending upon the composition of the particular sequence, however, the minimum values may be adjusted and are set as indicated above. An example of an alignment is shown in Figure 1.
- a suitable domain may be a variant (e.g., mutant or fragment) of a naturally-occurring domain sequence.
- a suitable domain may have a sequence having at least 70% (e.g., at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical to an amino acid sequence of a naturally- occurring domain found in a DNA polymerase of interest.
- sequences defining the N-terminal domain, exonuclease domain, palm, fingers, and/or thumb domains may correlate with certain enzymatic characteristics of DNA polymerases, such as, fidelity or error rate, elongation rate, processivity, and salt resistance.
- sequences defining the N-terminal, exonuclease, and/or thumb domain may correlate with the characteristics associated with elongation rate, processivity, thermostability, TMAC tolerance and/or salt resistance; and that sequences defining the palm and/or fingers domain may correlate with the characteristics associated with fidelity or error rate of DNA polymerases.
- domains correlative with high processivity, elongation rate, thermostability, TMAC tolerance and/or salt resistance may be defined by one or more of the following positive consensus sequences:
- a domain or domains correlative with high processivity, elongation rate, thermostability, TMAC tolerance and/or salt resistance may be defined by one or more of the following negative consensus sequences:
- Negative consensus sequence 1 (defining an N-terminal domain)
- Negative consensus sequence 2 (defining an exonuclease domain)
- a domain correlative with high fidelity may be defined by the following positive consensus sequence (defining palm and fingers domain):
- ESXEIXXXXLX (SEQ ID NO:36), wherein X is any amino acid or a peptide bond.
- a domain correlative with high fidelity may be defined by the following negative consensus sequence (defining palm and fingers domain):
- inventive methods in accordance with the present invention include steps of: (a) providing an N-terminal domain, an exonuclease domain, and/or a thumb domain based on a first DNA polymerase; (b) providing palm and/or fingers domain based on a second DNA polymerase; (c) combining the domains from step (a) and step (b) to form a chimeric polymerase.
- the first and the second DNA polymerases are characterized with at least one distinct characteristic.
- the first DNA polymerase may be characterized with high processivity, elongation rate, thermostability, TMAC tolerance and/or salt resistance and the second DNA polymerase may be characterized with high fidelity.
- the first DNA polymerase may be characterized with high fidelity and the second DNA polymerase may be characterized with high processivity, elongation rate, thermostability, TMAC tolerance and/or salt resistance.
- a chimeric polymerase engineered according to the invention has a processivity, elongation rate, thermostability, TMAC tolerance or salt resistance substantially similar to that of the first DNA polymerase and a fidelity substantially similar to that of the second DNA polymerase.
- a chimeric polymerases engineered according to the present invention has the fidelity higher than that of the first DNA polymerase and the processivity, elongation rate or salt resistance higher than that of the second DNA polymerase.
- inventive methods in accordance with the invention include a step of replacing a sequence within the palm- fingers domain of the DNA polymerase of interest with a corresponding sequence from a different DNA polymerase that is characterized with higher fidelity relative to the DNA polymerase of interest.
- inventive methods in accordance with the present invention include a step of replacing a sequence within the N- terminal domain, the exonuclease domain and/or the thumb domain of the DNA polymerase of interest with a corresponding sequence from a different DNA polymerase that is characterized with higher processivity, elongation rate, thermostability, TMAC tolerance or salt resistance relative to the DNA polymerase of interest.
- the present inventors have engineered a chimeric
- Kofu contains the N-terminal domain, the exonuclease domain and the thumb domain from KOD polymerase and the palm- fingers domain from Pfu polymerase.
- the sequence of Kofu polymerase is provided in SEQ ID NO: 16.
- the reciprocal chimera POD contains the N- terminal domain, the exonuclease domain and the thumb domain from Pfu polymerase and the palm- fingers domain from KOD polymerase.
- the sequence of POD polymerase is provided in SEQ ID NO: 15.
- the Kofu chimeric polymerase displays the approximate replication fidelity of Pfu but the elongation speed, processivity, thermostability, TMAC tolerance and PCR performance similar to KOD.
- the Pod chimeric polymerase displays the approximate replication fidelity of KOD but the elongation speed, processivity, thermostability, TMAC tolerance and PCR performance similar to Pfu.
- the present invention provides variants of Kofu chimeric polymerase that contain an amino acid sequence at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical to SEQ ID NO: 16 (Kofu amino acid sequence).
- variants of Kofu chimeric polymerase in accordance with the invention have processivity, elongation rate, thermostability, TMAC tolerance and/or fidelity substantially similar to Kofu.
- variants of Kofu chimeric polymerases in accordance with the present invention are defined by consensus sequence
- variants of Kofu chimeric polymerases in accordance with the present invention are defined by consensus sequence
- XGT (SEQ ID NO:39), wherein X is any amino acid or a peptide bond
- the present invention provide variants of POD chimeric polymerases that contain an amino acid sequence at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical to SEQ ID NO: 15 (Pod amino acid sequence).
- variants of POD chimeric polymerases in accordance with the present invention have processivity, elongation rate, thermostability, TMAC tolerance and/or fidelity substantially similar to POD.
- Standard recombinant DNA techniques e.g., restriction enzyme digestion, ligation, PCR
- Methods well known in the art may be applied to express and isolate chimeric DNA polymerases.
- Many bacterial expression vectors contain sequence elements or combinations of sequence elements allowing high level inducible expression of the protein encoded by a foreign sequence. Expression vectors are commercially available from, for example, Novagen (http://www.emdbiosciences.com/html/NVG/AHTables.htmW).
- bacteria expressing an integrated inducible form of the T7 RNA polymerase gene may be transformed with an expression vector bearing a chimeric DNA polymerase gene linked to the T7 promoter.
- Induction of the T7 RNA polymerase by addition of an appropriate inducer, for example, isopropyl-p-D-thiogalactopyranoside (IPTG) for a lac-inducible promoter, induces the high level expression of the chimeric gene from the T7 promoter.
- an appropriate inducer for example, isopropyl-p-D-thiogalactopyranoside (IPTG) for a lac-inducible promoter
- E. coli strain BL-21 is commonly used for expression of exogenous proteins since it is protease deficient relative to other strains of E. coli. For situations in which codon usage for the particular polymerase gene differs from that normally seen in E.
- coli genes there are strains of BL-21 that are modified to carry tRNA genes encoding tRNAs with rarer anticodons (for example, argU, ileY, leuW, and proL tRNA genes), allowing high efficiency expression of cloned chimeric genes (several BL21 -CODON PLUSTM cell strains carrying rare-codon tRNAs are available from Stratagene, for example).
- rarer anticodons for example, argU, ileY, leuW, and proL tRNA genes
- genes encoding DNA polymerases may be codon optimized to facilitate expression in E. coli. Codon optimized sequences can be chemically synthesized.
- DNA polymerase mutants may be isolated by an ammonium sulfate fractionation, followed by Q Sepharose and DNA cellulose columns, or by adsorption of contaminants on a HiTrap Q column, followed by gradient elution from a HiTrap heparin column.
- Chimeric DNA polymerases of the present invention may be used for any methods involving polynucleotide synthesis.
- Polynucleotide synthesis methods are well known to a person of ordinary skill in the art and can be found, for example, in Molecular Cloning second edition, Sambrook et al., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y. (1989).
- chimeric DNA polymerases of the present invention have a variety of uses in recombinant DNA technology including, but not limited to, labeling of DNA by nick translation, second-strand cDNA synthesis in cDNA cloning, DNA sequencing, and amplifying, detecting, and/or cloning nucleic acid sequences using polymerase chain reaction (PCR).
- PCR polymerase chain reaction
- the invention provides robust, fast, and accurate enzymes for PCR.
- PCR refers to an in vitro method for amplifying a specific polynucleotide template sequence.
- the technique of PCR is described in numerous publications, including, PCR: A Practical Approach, M. J. McPherson, et al., IRL Press (1991), PCR Protocols: A Guide to Methods and Applications, by Innis, et al. , Academic Press (1990), and PCR Technology : Principals and Applications for DNA Amplification, H. A. Erlich, Stockton Press (1989).
- PCR is also described in many U. S. Patents, including U. S. Patent Nos.
- Chimeric DNA polymerases with higher processivity, elongation rate and/or fidelity are expected to reduce error rate, improve efficiency and success rate of long-range amplification (higher yield, longer targets amplified), and/or reduce the amount of required DNA template.
- the present invention can be used in PCR applications including, but are not limited to, i) hot-start PCR which reduces non-specific amplification; ii) touch-down PCR which starts at high annealing temperature, then decreases annealing temperature in steps to reduce non-specific PCR product; iii) nested PCR which synthesizes more reliable product using an outer set of primers and an inner set of primers; iv) inverse PCR for amplification of regions flanking a known sequence.
- DNA is digested, the desired fragment is circularized by ligation, then PCR using primer complementary to the known sequence extending outwards;
- AP-PCR arbitrary primed
- RAPD random amplified polymorphic DNA.
- RACE rapid amplification of cDNA ends
- the method amplifies 3 ' or 5 ' ends of cDNAs generating fragments of cDNA with only one specific primer each (plus one adaptor primer). Overlapping RACE products can then be combined to produce full length cDNA; viii) DD-PCR (differential display PCR) which is used to identify differentially expressed genes in different tissues.
- First step in DD-PCR involves RT-PCR, then amplification is performed using short, intentionally nonspecific primers; ix) Multiplex- PCR in which two or more unique targets of DNA sequences in the same specimen are amplified simultaneously.
- One DNA sequence can be use as control to verify the quality of PCR; x) Q/C-PCR (Quantitative comparative) which uses an internal control DNA sequence (but of different size) which compete with the target DNA (competitive PCR) for the same set of primers; xi) Recusive PCR which is used to synthesize genes.
- Oligonucleotides used in this method are complementary to stretches of a gene (>80 bases), alternately to the sense and to the antisense strands with ends overlapping (-20 bases); xii) Asymmetric PCR; xiii) In Situ PCR; xiv) Site-directed PCR Mutagenesis; xv) DOP-PCR that uses partially degenerate primers for whole-genome amplification; xvi) quantitative PCR using SYBR green or oligonucleotide probes to detect amplification; xvii) whole-genome amplification using adaptor-ligated DNA fragment libraries as template, and xviii) error-prone PCR in which conditions are optimized to give an increased number of mutations in the PCR product.
- kits which include a package unit having one or more containers containing chimeric DNA polymerases of the invention and compositions thereof.
- the present invention provides kits further including containers of various reagents used for polynucleotide synthesis, including synthesis in PCR.
- kits in accordance with the present invention may also contain one or more of the following items: polynucleotide precursors, primers, buffers, instructions, and controls.
- Kits may include containers of reagents mixed together in suitable proportions for performing the methods in accordance with the invention.
- Reagent containers preferably contain reagents in unit quantities that obviate measuring steps when performing the subject methods.
- the two enzymes we chose to include in this experiment were Pyroccocus furiosus DNA polymerase ⁇ Pfu) and Thermococcus Kodarensis (KOD) DNA polymerases.
- the two enzymes have similar domain structure and have a 79% identity at the amino acid level using blastP alignments (see Table 2).
- the domain structures of Pfu and KOD are illustrated in Figure 1. Table 2. ClustalW alignment of Pfu and KOD
- PFU 181 VEWSSEREMIKRFLRIIREKDPDIIVTYNGDSFDFPYLAKRAEKLGIKLTIGRDGSEPK 240
- Pfu and KOD have very distinct phenotypic characteristics, in particular, with respect to elongation rate, processivity and error rate (See Table 3):
- Restriction sites were inserted into the codon-optimized nucleotide sequence of KOD and Pfu polymerases at positions that approximately flank the polymerase domain of the enzymes (see Example 2).
- PvuII and EcoRI sites flanking the polymerase domain were used to replace the polymerase domain of Pfu with that of KOD to generate the chimera deemed Pod ( Figure 2).
- This chimera contains the N-terminal domain, the 3 '-5' exonuclease domain and the thumb domain of Pfu and the palm and fingers domain of KOD.
- the reciprocal swap, yielding the chimera Ko fu was generated by replacing the polymerase domain (palm and fingers) of KOD with that of Pfu.
- the two codon optimized genes were chemically synthesized and cloned into pUC19 by Codon Devices (Cambridge, Massachusetts) resulting in SEQ ID NO: 7 for Pfu polymerase I and SEQ ID NO: 8 for KOD polymerase I.
- Example 3 Cloning of codon optimized KOD and Pfu polymerase I sequences into expression vector pKBexp.
- KOD SEQ ID NO: 8
- Pfu SEQ ID NO: 7
- the pKBexp vector contains two Eco3 II sites with non-complementary overhangs enabling directional cloning of inserts using a single restriction enzyme.
- KOD and Pfu polymerase genes were designed with two flanking Eco31I sites that enabled directional and in-frame cloning into pKBexp.
- polymerase I genes were designed with restriction sites that approximately flank the finger and palm domains of KOD and Pfu polymerases.
- the KOD codon optimized sequence contains a PvuII restriction site and an EcoRI restriction site.
- the Pfu codon optimized sequence contains a PvuII restricition site and an EcoRI restriction site.
- POD The construct deemed POD was created by ligation of 30 ng of the 4.7 kb Pfu large fragment (aa residues 1 to 335 and 567 to 778 of Pfu DNA polymerase with 10 ng of the 0.7 kb KOD small fragment (corresponding to amino acid residues 336 to 565 of KOD DNA polymerase SEQ ID NO: 11).
- POD thus includes N-terminal, exonuclease and thumb domains from Pfu DNA polymerase and palm and finger domains from KOD.
- the construct deemed Ko fu was made by ligation of 30 ng of the 4.7 kb KOD large fragment (corresponding to amino acid residues 1 to 335 and 566 to 777 of KOD DNA polymerase SEQ ID NO:11) with 10 ng of the 0.7 kb Pfu small fragment (corresponding to amino acid residues 336 to 566 of Pfu DNA polymerase SEQ ID NO: 11).
- Ko fu thus includes N-terminal, exonuclease and thumb domains from KOD DNA polymerase and palm and finger domains from Pfu.
- the ligation reactions were used to transform E. coli DHlOB.
- the construction of Pod (SEQ ID NO: 13) and Ko fu (SEQ ID NO: 14) was confirmed by DNA sequencing.
- the domain structures of POD and Ko fu are illustrated in Figure 1. Expression and purification of chimeric polymerases are done using methods known in the art, for example, as reviewed in "Detailed description of the invention.”
- the primer template mix contained the following: 20 mM Tris-HCl pH 8.0, 2 mM MgCl 2 , 6 mM (NH4) 2 SO 4 , 0.6 mM dNTP, 0.6 ⁇ M each of primers HPRTl-Fl (5'-tttggaaacatctggagtcct -3' (SEQ ID NO:40)) and HPRTl-Rl (5'- gcccaaagggaactgatagtc -3' (SEQ ID NO:41)), 2 ng human genomic DNA per ⁇ l, and 25 or 50 mM KCl (25 mM for Pfu and Pod, 50 mM for KOD and Ko fu).
- the amplifications were performed with the following cycling protocol: 3 minutes at 95 0 C, 35 x (20 seconds at 98 0 C, 20 seconds at 60 0 C, 20 seconds at 72 0 C), 20 seconds at 72 0 C.
- the PCR products were analysed on an agarose gel (see Figure 3). As illustrated in Figure 3, no amplification was observed for Pfu after pre-incubation of the enzyme for 4 hours at 98 0 C. In contrast, KOD, Kofu and Pod were able to amplify a PCR product for all time points tested.
- LacIQZalfa plasmid template (equivalent to 25 ng of lad target) and 2.5U of each enzyme to amplify the 1.386 Kb lacIOZalpha fragment.
- the PCR conditions were as follows: amplification with Pfu and Pod were done in Pfu buffer (Fermentas); KOD and Kofu in Novagen KOD buffer 1. Final concentrations of 2 mM MgC12, 0.4 ⁇ M each of primers M13-40 (GTTTTCCCAGTCACGAC (SEQ ID NO:42)) and
- PKBlac-lR (GGTATCTTTATAGTCCTGTCG (SEQ ID NO:43)) and 0.2 mM each dNTP. Cycling parameters for Pfu and Pod were: 94 0 C 4 minutes, 30 x (94 0 C 15 seconds, 55 0 C 15 seconds, 72 0 C 3 minutes), 72 0 C 6 minutes. Cycling parameters for KOD and Kofu were: 94 0C 2 minutes, 30 x (98 0 C 15 seconds, 55 0 C 2 seconds, 72 0 C 20 seconds), 72 0 C 30 seconds.
- PCR product yields were quantitated by means of gel electrophoresis and the number of template doublings were calculated.
- PCR products were digested with Xbal, Ncol and Dpnl, gel-purified (without exposure to UV light) and ligated into Xbal-NcoI-digested pKB-LacIQZalpha.
- E.coli was transformed with the ligation mixtures and the cells were plated onto LB-Amp-X-gal plates. The number of blue colonies, white colonies and total number of colonies were recorded.
- Exemplary results are summarized in Table 4. As shown in Table 4, Pfu and Kofu have similar fidelity and that their fidelity is higher than that of KOD and Pod.
- Processivity can be determined and calculated using assays described in
- ssM13mpl8 DNA is added to 1.6 pmoles of ssM13mpl8 DNA in the presence of 20 mM Tris-HCl pH 8.0, 25 mM KCl, 2.5 mM MgC12, 0.3 mM dNTP in a 16 microL volume.
- the primer is annealed to the template by heating to 95 0 C for 2 minutes followed by slow cooling to 72 0 C in a thermocycler at a rate of 0.1 °C/second, incubation for 10 minutes at 72 0 C and further cooling at 0.1 °C/second to 4 0 C.
- the polymerases are diluted in 20 mM Tris-HCl pH 8.0, 25 mM KCl.
- the primed template and the diluted polymerases are heated to 72 0 C and the reaction is started by adding 4 ⁇ l diluted polymerase to 16 ⁇ l of primed template.
- the polymerases are diluted to give polymerase template ratios of 1 : 10 - 1 : 10000.
- the reactions are terminated after various timepoints by adding EDTA to a final concentration of 10 mM.
- extension reactions are analyzed on an ABI 3130XL Genetic Analyzer.
- the median product length is determined for each reaction.
- the median product length is defined as the length of the product at which the total fluorescence intensity of all products up to that length equals 50% of the sum of fluorescence intensities of all detectable products.
- the traces for those samples where the median product length does not change with a change in polymerase concentration or incubation time are used to calculate the processivity according to Von Hippel et al. (Von Hippel et al. NY Acad Sd 1094; 726:118-131).
- Each peak (I) with a fluorescence level significantly above background level is integrated to give the fluorescence intensity of that peak (ni).
- the total fluorescence intensity (nT) is the sum of the fluorescence of all peaks.
- the integration data are plotted as log(ni/nT) vs n-1, where n is the number of nucleotides incorporated.
- Pi the microscopic processivity factor, is defined as the probability of not terminating extension at position i.
- the average primer extension length is determined from 1/(1-Pi).
- the protein concentration of the purified KOD, Pfu, Kofu and Pod where determined using a Bioanalyzer 2100 (Agilent, Santa Clara, CA, USA) with the Protein 230 Kit from the same supplier.
- the polymerases were tested in real-time PCR with increasing amounts of KCl added.
- the reactions were performed in a 20 ⁇ l volume containing 20 mM Tris-HCl pH 8.0, 6 mM (NH 4 ) 2 SO 4 , 2 mM MgCl 2 , 3% DMSO, 10 ng polymerase, 20 ng human genomic DNA, 0.3 mM each dNTP, 0.25X SYBR Green (Invitrogen, Carlsbad, CA, USA).
- a diluted stock 2OX SYBR Green in DMSO was made), 0.3 ⁇ M forward primer HPRTl-Fl (5'-tttggaaacatctggagtcct -3' (SEQ ID NO:40)) and 0.3 ⁇ M reverse primer HPRTl -Rl (5'- gcccaaagggaactgatagtc -3' (SEQ ID NO:41)).
- KCl was added to final concentrations of 10, 25, 50, 75, 100 or 125 mM.
- PCR amplification was performed in a Corbett 6000 HRM real-time thermocycler (Corbett Life Science, Sidney, Australia) with the following cycling protocol: 3 minutes at 95 0 C, 40 cycles of (10 seconds at 95 0 C, 20 seconds at 60 0 C, 20 seconds at 72 0 C, data acquisition), followed by a melting curve analysis step of: ramp from 72 0 C to 95 0 C in 1 0 C steps, wait for 5 seconds before data acquisition at the end of each step. 8 ⁇ l of each sample was analysed on a 1.5% agarose gel. 5 ⁇ l of Fermentas GeneRulerTM Mix, cat no. SM0333 (Fermentas, Vilnius, Lithuania) was loaded onto the gel as a DNA marker. Exemplary results are shown in Figure 4.
- TMAC tetra-methyl ammonium chloride
- TMAC TMAC added.
- the reactions were performed in a 20 ⁇ l volume containing 20 mM Tris-HCl pH 8.0, 6 mM (NH 4 ) 2 SO 4 , 2 mM MgCl 2 , 25 mM KCl, 10 ng polymerase, 20 ng human genomic DNA, 0.3 mM each dNTP, 0.25X SYBR Green (Invitrogen, Carlsbad, CA, USA.
- a diluted stock 2OX SYBR Green in DMSO was made), 0.3 ⁇ M forward primer HPRTl-Fl (5'-tttggaaacatctggagtcct -3' (SEQ ID NO:40)) and 0.3 ⁇ M reverse primer HPRTl -Rl (5'- gcccaaagggaactgatagtc -3' (SEQ ID NO:41)).
- TMAC was added to final concentrations of 0, 10, 20, 40, 60, 80, 100 or 120 mM.
- PCR amplification was performed in a Corbett 6000 HRM real-time thermocycler (Corbett Life Science, Sidney, Australia) with the following cycling protocol: 3 minutes at 95 0 C, 40 cycles of (10 seconds at 95 0 C, 20 seconds at 50 0 C, 20 seconds at 72 0 C, data acquisition), followed by a melting curve analysis step of: ramp from 72 0 C to 95 0 C in 1 0 C steps, wait for 5 seconds before data acquisition at the end of each step. 8 ⁇ l of each sample was analysed on a 1.5% agarose gel. 5 ⁇ l of Fermentas GeneRulerTM Mix, cat no. SM0333 (Fermentas, Vilnius, Lithuania) was loaded onto the gel as a DNA marker. Exemplary results are shown in Figure 5.
- Kofu-II (SEQ ID NO:26) is made by replacing amino acid residues 305 to 615 of KOD (SEQ ID NO: 12) with amino acids 305 to 616 of Pfu (SEQ ID NO:10).
- Pod-II (SEQ ID NO:27) is made by replacing amino acids 305 to 616 of Pfu (SEQ ID NO: 10) with amino acids 305 to 615 of KOD (SEQ ID NO: 12).
- Kofu-III (SEQ ID NO:28) is made by replacing amino acid residues 396 to
- the 5 ' and 3 ' sequences can be designed so that the overhangs, after digestion of the DNA with Eco31I, are complementary to the overhangs in a particular expression vector (e.g., pKB). Codon optimization and gene synthesis is performed by GeneArt Gmbh. Expression and purification of chimeric polymerases are done using methods known in the art, for example, as reviewed in "Detailed description of the invention". The thermostability, fidelity, processivity, salt resistance and TMAC resistance of the chimeric polymerses are determined as described in Examples 5 through 9.
- Chimera 9NIi can be made by replacing the palm and finger region of the 9N polymerase with the palm and finger region of the T. litoralis polymerase.
- 9NIi is made by replacing amino acids 347 to 580 of 9N polymerase (SEQ ID NO: 18) with amino acids 349 to 583 of T. litoralis polymerase (SEQ ID NO: 19).
- SEQ ID NO: 20 The sequence of the coding region of 9NIi is provided as SEQ ID NO:20.
- Chimera LiN9 can be made by replacing the palm and finger domain of the
- LiN9 is made by replacing amino acids 349 to 583 of T. litoralis polymerase (SEQ ID NO: 19) with amino acids 347 to 580 of 9 degrees N-7 polymerase (SEQ ID NO: 18).
- SEQ ID NO: 19 The sequence of the coding region of LiN9 is provided as SEQ ID NO:21.
- Example 12 Chimeras of T. gorgonarius and T. zilligii type B DNA polymerases
- Chimera GoZi can be made by replacing the palm and finger region of the T. gorgonarius polymerase with the palm and finger region of the T. zilligii polymerase.
- GoZi is made by replacing amino acids 391 to 559 of T. gorgonarius polymerase (SEQ ID NO:22) with amino acids 391 to 559 of T. zilligii polymerase (SEQ ID NO:23).
- SEQ ID NO:24 The sequence of the resulting chimera GoZi is provided as SEQ ID NO:24.
- Chimera ZiGo can be made by replacing the palm and finger domain of the
- ZiGo is made by replacing amino acids 391 to 559 of T. zilligii polymerase (SEQ ID NO:23) with amino acids 391 to 559 of T. gorgonarius polymerase (SEQ ID NO:22).
- SEQ ID NO:25 The sequence of the coding region of ZiGo is provided as SEQ ID NO:25.
- AAAAGATGCG AAAAGTTGGG CATAAATTTC GCTCTTGGTC GAGACGGGTC AGAGCCTAAA 721 ATCCAGCGTA TGGGAGATCG CTTTGCGGTT GAAGTGAAAG GCCGGATTCA TTTCGACCTG
- Sequence 17 (SEQ ID NO: 17) >pLACIQZa
- Thermococcus sp. 9 degrees N-7 DNA polymerase amino acid sequence (ace no. U47108)
- the invention includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process.
- the invention also includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process.
- the invention encompasses variations, combinations, and permutations in which one or more limitations, elements, clauses, descriptive terms, etc., from one or more of the claims is introduced into another claim dependent on the same base claim (or, as relevant, any other claim) unless otherwise indicated or unless it would be evident to one of ordinary skill in the art that a contradiction or inconsistency would arise.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011534889A JP2012507986A (en) | 2008-11-03 | 2009-11-03 | Chimeric DNA polymerase |
EP15160891.6A EP2927317B1 (en) | 2008-11-03 | 2009-11-03 | Chimeric dna polymerases |
ES09829689T ES2571446T3 (en) | 2008-11-03 | 2009-11-03 | Chimeric DNA polymerases |
US13/127,420 US9023633B2 (en) | 2008-11-03 | 2009-11-03 | Chimeric DNA polymerases |
CA2742593A CA2742593C (en) | 2008-11-03 | 2009-11-03 | Chimeric dna polymerases |
EP09829689.0A EP2352818B1 (en) | 2008-11-03 | 2009-11-03 | Chimeric dna polymerases |
CN2009801510634A CN102257136A (en) | 2008-11-03 | 2009-11-03 | Chimeric DNA polymerases |
US14/270,304 US9388396B2 (en) | 2008-11-03 | 2014-05-05 | Chimeric DNA polymerases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11086208P | 2008-11-03 | 2008-11-03 | |
US61/110,862 | 2008-11-03 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/127,420 A-371-Of-International US9023633B2 (en) | 2008-11-03 | 2009-11-03 | Chimeric DNA polymerases |
US14/270,304 Continuation US9388396B2 (en) | 2008-11-03 | 2014-05-05 | Chimeric DNA polymerases |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010062776A2 true WO2010062776A2 (en) | 2010-06-03 |
WO2010062776A3 WO2010062776A3 (en) | 2010-08-19 |
Family
ID=42226349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/063166 WO2010062776A2 (en) | 2008-11-03 | 2009-11-03 | Chimeric dna polymerases |
Country Status (8)
Country | Link |
---|---|
US (2) | US9023633B2 (en) |
EP (2) | EP2927317B1 (en) |
JP (3) | JP2012507986A (en) |
CN (1) | CN102257136A (en) |
CA (1) | CA2742593C (en) |
ES (2) | ES2716402T3 (en) |
HK (1) | HK1216032A1 (en) |
WO (1) | WO2010062776A2 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102392000A (en) * | 2011-11-07 | 2012-03-28 | 李志茹 | High-temperature-resistant Pyrolobus polymerase and efficient expression plasmid and application thereof |
CN104250641A (en) * | 2013-06-28 | 2014-12-31 | 思洛生物技术股份有限公司 | High fidelity DNA polymerase and preparation and application thereof |
WO2016077795A1 (en) * | 2014-11-14 | 2016-05-19 | Illumina, Inc. | Polymerases |
WO2016033315A3 (en) * | 2014-08-27 | 2016-06-02 | New England Biolabs, Inc. | Synthon formation |
WO2017127510A2 (en) | 2016-01-19 | 2017-07-27 | Board Of Regents, The University Of Texas System | Thermostable reverse transcriptase |
US9963687B2 (en) | 2014-08-27 | 2018-05-08 | New England Biolabs, Inc. | Fusion polymerase and method for using the same |
WO2020144480A1 (en) * | 2019-01-09 | 2020-07-16 | 3Cr Bioscience Ltd. | Method for detecting a nucleic acid sequence |
GB2587177A (en) * | 2019-01-09 | 2021-03-24 | 3Cr Bioscience Ltd | Polymerase |
US10961555B2 (en) | 2008-11-03 | 2021-03-30 | Kapa Biosystems, Inc. | Modified type A DNA polymerases |
US10975361B2 (en) | 2011-01-14 | 2021-04-13 | Kapa Biosystems, Inc. | Modified DNA polymerases for improved amplification |
US11312944B2 (en) | 2016-12-19 | 2022-04-26 | Quantum-Si Incorporated | Polymerizing enzymes for sequencing reactions |
US11866785B2 (en) | 2017-10-27 | 2024-01-09 | Board Of Regents, The University Of Texas System | Tumor specific antibodies and T-cell receptors and methods of identifying the same |
US11959105B2 (en) | 2019-06-28 | 2024-04-16 | Quantum-Si Incorporated | Polymerizing enzymes for sequencing reactions |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2927317B1 (en) | 2008-11-03 | 2018-12-19 | Kapa Biosystems, Inc. | Chimeric dna polymerases |
US9309501B2 (en) | 2012-12-24 | 2016-04-12 | Industrial Technology Research Institute | Isolated DNA polymerases, kits and applications thereof |
WO2015019658A1 (en) * | 2013-08-06 | 2015-02-12 | 東洋紡株式会社 | Nucleic acid amplification method |
DK3161154T3 (en) * | 2014-06-27 | 2020-06-15 | Illumina Inc | Modified polymerases for improved incorporation of nucleotide analogues |
JP6619152B2 (en) * | 2015-05-08 | 2019-12-11 | 国立研究開発法人産業技術総合研究所 | Chimeric protein with flavin adenine dinucleotide-dependent glucose dehydrogenase activity |
CN106867978A (en) * | 2015-12-10 | 2017-06-20 | 江苏众红生物工程创药研究院有限公司 | One kind restructuring high-fidelity DNA polymerase and its encoding gene and expression |
JP6980375B2 (en) * | 2015-12-11 | 2021-12-15 | 東洋紡株式会社 | Nucleic acid amplification reagent and nucleic acid amplification method |
JP6969089B2 (en) * | 2015-12-11 | 2021-11-24 | 東洋紡株式会社 | Nucleic acid amplification composition and nucleic acid amplification method |
LT3402880T (en) | 2016-01-15 | 2024-03-12 | Thermo Fisher Scientific Baltics Uab | Thermophilic dna polymerase mutants |
US20190176153A1 (en) | 2016-05-18 | 2019-06-13 | Roche Sequencing Solutions, Inc. | Quantitative real time pcr amplification using an electrowetting-based device |
FR3052462A1 (en) * | 2016-06-14 | 2017-12-15 | Dna Script | POLYMERASE DNA VARIANTS OF THE POLX FAMILY |
CN106011100A (en) * | 2016-08-08 | 2016-10-12 | 吴江近岸蛋白质科技有限公司 | Pfu DNA polymerase and preparation method thereof |
CN106754816B (en) * | 2017-02-24 | 2020-10-27 | 依科赛生物科技(太仓)有限公司 | High-fidelity rapid amplification fusion enzyme and preparation method thereof |
US11618891B2 (en) | 2017-06-26 | 2023-04-04 | Thermo Fisher Scientific Baltics Uab | Thermophilic DNA polymerase mutants |
US10738286B2 (en) | 2017-06-30 | 2020-08-11 | Codexis, Inc. | T7 RNA polymerase variants |
JP2020530266A (en) | 2017-06-30 | 2020-10-22 | コデクシス, インコーポレイテッド | T7 RNA polymerase variant |
CN111684064A (en) | 2018-01-19 | 2020-09-18 | 生物辐射实验室股份有限公司 | Mutant DNA polymerases |
CN117802065A (en) * | 2018-09-03 | 2024-04-02 | 深圳华大生命科学研究院 | Recombinant KOD polymerase with improved polymerization activity |
CN109628424B (en) * | 2018-12-31 | 2022-04-26 | 苏州近岸蛋白质科技股份有限公司 | Novel chimeric DNA polymerase and preparation method thereof |
WO2021127848A1 (en) * | 2019-12-23 | 2021-07-01 | 深圳华大生命科学研究院 | Chimeric dna polymerase and application thereof |
CN113604450B (en) * | 2021-08-18 | 2023-08-18 | 华南理工大学 | KOD DNA polymerase mutant and preparation method and application thereof |
CN113755465A (en) * | 2021-09-23 | 2021-12-07 | 武汉爱博泰克生物科技有限公司 | Chimeric DNA polymerase and method for preparing same |
WO2023082266A1 (en) * | 2021-11-15 | 2023-05-19 | 深圳华大生命科学研究院 | Chimeric dna polymerase and use thereof |
Citations (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US4889818A (en) | 1986-08-22 | 1989-12-26 | Cetus Corporation | Purified thermostable enzyme |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US5023171A (en) | 1989-08-10 | 1991-06-11 | Mayo Foundation For Medical Education And Research | Method for gene splicing by overlap extension using the polymerase chain reaction |
US5066584A (en) | 1988-09-23 | 1991-11-19 | Cetus Corporation | Methods for generating single stranded dna by the polymerase chain reaction |
US5075216A (en) | 1988-09-23 | 1991-12-24 | Cetus Corporation | Methods for dna sequencing with thermus aquaticus dna polymerase |
US5079352A (en) | 1986-08-22 | 1992-01-07 | Cetus Corporation | Purified thermostable enzyme |
US5091310A (en) | 1988-09-23 | 1992-02-25 | Cetus Corporation | Structure-independent dna amplification by the polymerase chain reaction |
US5104792A (en) | 1989-12-21 | 1992-04-14 | The United States Of America As Represented By The Department Of Health And Human Services | Method for amplifying unknown nucleic acid sequences |
US5545552A (en) | 1990-12-03 | 1996-08-13 | Stratagene | Purified thermostable pyrococcus furiosus DNA polymerase I |
US5556772A (en) | 1993-12-08 | 1996-09-17 | Stratagene | Polymerase compositions and uses thereof |
WO1998033900A1 (en) | 1997-01-31 | 1998-08-06 | Japan Science And Technology Corporation | Method and apparatus for predicting protein function site, method for improving protein function, and function-improved protein |
US5866395A (en) | 1990-12-03 | 1999-02-02 | Stratagene | Purified thermostable pyrococcus furiosus DNA polymerase I |
US5948663A (en) | 1990-12-03 | 1999-09-07 | Stratagene | Purified thermostable pyrococcus furiosus DNA polymerase I |
WO2001032887A1 (en) | 1999-10-29 | 2001-05-10 | Stratagene | Compositions and methods utilizing dna polymerases |
WO2001061015A2 (en) | 2000-02-17 | 2001-08-23 | Qiagen Gmbh | Thermostable chimeric nucleic acid polymerases and uses thereof |
WO2001092501A1 (en) | 2000-05-26 | 2001-12-06 | Mj Bioworks, Inc. | Improved nucleic acid modifying enzymes |
US20020119461A1 (en) | 2000-07-12 | 2002-08-29 | Invitrogen Corporation | High fidelity polymerases and uses thereof |
US20020119471A1 (en) | 1998-08-18 | 2002-08-29 | Rheins Lawrence A. | Method for detection of biological factors in epidermis |
WO2005113760A2 (en) | 2004-05-20 | 2005-12-01 | The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | Thermostable y-family polymerases and chimeras |
WO2005118866A2 (en) | 2004-05-26 | 2005-12-15 | Stratagene California | COMPOSITIONS AND METHODS FOR SYNTHESIZING cDNA |
US20060281109A1 (en) | 2005-05-10 | 2006-12-14 | Barr Ost Tobias W | Polymerases |
US20070190538A1 (en) | 2005-07-29 | 2007-08-16 | Applera Corporation | Chimeric polymerases |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69232511T2 (en) | 1991-12-18 | 2002-10-24 | New England Biolabs Inc | Purified thermostable DNA polymerase from Pyrococcus species |
JPH05328696A (en) | 1992-05-18 | 1993-12-10 | Sony Corp | Movable coil type actuator |
JP3132624B2 (en) | 1994-05-09 | 2001-02-05 | 東洋紡績株式会社 | DNA polymerase gene derived from hyperthermophilic archaeon and uses thereof |
US6033859A (en) | 1996-05-24 | 2000-03-07 | Toyo Boseki Kabushiki Kaisha | Thermostable DNA polymerase from a hyperthermophilic archaeon strain KOD1 |
DE19810879A1 (en) | 1998-03-13 | 1999-09-16 | Roche Diagnostics Gmbh | New chimeric polymerase with 5'-3'-polymerase activity, and optionally proofreading activity, used for polymerase chain reactions and sequencing |
GB9921318D0 (en) | 1999-09-09 | 1999-11-10 | Kristensen Tom | Chimeric molecules |
DE60141097D1 (en) | 2000-05-11 | 2010-03-11 | Toyo Boseki | MODIFIED THERMOSTABILE DNA POLYMERASE OF PYROCOCCUS KODAKARAENSIS |
GB2382321A (en) | 2001-11-21 | 2003-05-28 | Doyen Medipharm Ltd | Process and apparatus for cutting sheets |
US7960157B2 (en) * | 2002-12-20 | 2011-06-14 | Agilent Technologies, Inc. | DNA polymerase blends and uses thereof |
AU2004225520A1 (en) | 2003-03-25 | 2004-10-14 | Stratagene | DNA polymerase fusions and uses thereof |
US20040244310A1 (en) | 2003-03-28 | 2004-12-09 | Blumberg Marvin R. | Data center |
JP4271080B2 (en) | 2004-05-19 | 2009-06-03 | オリンパス株式会社 | Endoscope treatment device |
CN101365807A (en) | 2005-12-22 | 2009-02-11 | 加利福尼亚太平洋生物科学股份有限公司 | Polymerases for nucleotide analogue incorporation |
JP2007298879A (en) | 2006-05-02 | 2007-11-15 | C & C:Kk | Stroboscopic equipment |
US8962293B2 (en) | 2006-10-18 | 2015-02-24 | Roche Molecular Systems, Inc. | DNA polymerases and related methods |
WO2008051530A2 (en) | 2006-10-23 | 2008-05-02 | Pacific Biosciences Of California, Inc. | Polymerase enzymes and reagents for enhanced nucleic acid sequencing |
EP2927317B1 (en) | 2008-11-03 | 2018-12-19 | Kapa Biosystems, Inc. | Chimeric dna polymerases |
US8481685B2 (en) | 2008-11-03 | 2013-07-09 | Kapa Biosystems | Modified DNA polymerases |
JP5328696B2 (en) | 2010-03-01 | 2013-10-30 | 淀川ヒューテック株式会社 | Double layer belt |
-
2009
- 2009-11-03 EP EP15160891.6A patent/EP2927317B1/en active Active
- 2009-11-03 ES ES15160891T patent/ES2716402T3/en active Active
- 2009-11-03 CN CN2009801510634A patent/CN102257136A/en active Pending
- 2009-11-03 ES ES09829689T patent/ES2571446T3/en active Active
- 2009-11-03 EP EP09829689.0A patent/EP2352818B1/en active Active
- 2009-11-03 US US13/127,420 patent/US9023633B2/en active Active
- 2009-11-03 WO PCT/US2009/063166 patent/WO2010062776A2/en active Application Filing
- 2009-11-03 JP JP2011534889A patent/JP2012507986A/en not_active Withdrawn
- 2009-11-03 CA CA2742593A patent/CA2742593C/en active Active
-
2014
- 2014-05-05 US US14/270,304 patent/US9388396B2/en active Active
-
2015
- 2015-06-01 JP JP2015111259A patent/JP6150847B2/en active Active
-
2016
- 2016-04-07 HK HK16103943.4A patent/HK1216032A1/en unknown
- 2016-11-10 JP JP2016219403A patent/JP2017029172A/en active Pending
Patent Citations (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683202B1 (en) | 1985-03-28 | 1990-11-27 | Cetus Corp | |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683195B1 (en) | 1986-01-30 | 1990-11-27 | Cetus Corp | |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US4889818A (en) | 1986-08-22 | 1989-12-26 | Cetus Corporation | Purified thermostable enzyme |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US5079352A (en) | 1986-08-22 | 1992-01-07 | Cetus Corporation | Purified thermostable enzyme |
US5066584A (en) | 1988-09-23 | 1991-11-19 | Cetus Corporation | Methods for generating single stranded dna by the polymerase chain reaction |
US5075216A (en) | 1988-09-23 | 1991-12-24 | Cetus Corporation | Methods for dna sequencing with thermus aquaticus dna polymerase |
US5091310A (en) | 1988-09-23 | 1992-02-25 | Cetus Corporation | Structure-independent dna amplification by the polymerase chain reaction |
US5023171A (en) | 1989-08-10 | 1991-06-11 | Mayo Foundation For Medical Education And Research | Method for gene splicing by overlap extension using the polymerase chain reaction |
US5104792A (en) | 1989-12-21 | 1992-04-14 | The United States Of America As Represented By The Department Of Health And Human Services | Method for amplifying unknown nucleic acid sequences |
US5545552A (en) | 1990-12-03 | 1996-08-13 | Stratagene | Purified thermostable pyrococcus furiosus DNA polymerase I |
US5866395A (en) | 1990-12-03 | 1999-02-02 | Stratagene | Purified thermostable pyrococcus furiosus DNA polymerase I |
US5948663A (en) | 1990-12-03 | 1999-09-07 | Stratagene | Purified thermostable pyrococcus furiosus DNA polymerase I |
US5556772A (en) | 1993-12-08 | 1996-09-17 | Stratagene | Polymerase compositions and uses thereof |
WO1998033900A1 (en) | 1997-01-31 | 1998-08-06 | Japan Science And Technology Corporation | Method and apparatus for predicting protein function site, method for improving protein function, and function-improved protein |
US20020119471A1 (en) | 1998-08-18 | 2002-08-29 | Rheins Lawrence A. | Method for detection of biological factors in epidermis |
WO2001032887A1 (en) | 1999-10-29 | 2001-05-10 | Stratagene | Compositions and methods utilizing dna polymerases |
WO2001061015A2 (en) | 2000-02-17 | 2001-08-23 | Qiagen Gmbh | Thermostable chimeric nucleic acid polymerases and uses thereof |
WO2001092501A1 (en) | 2000-05-26 | 2001-12-06 | Mj Bioworks, Inc. | Improved nucleic acid modifying enzymes |
US20020119461A1 (en) | 2000-07-12 | 2002-08-29 | Invitrogen Corporation | High fidelity polymerases and uses thereof |
WO2005113760A2 (en) | 2004-05-20 | 2005-12-01 | The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | Thermostable y-family polymerases and chimeras |
WO2005118866A2 (en) | 2004-05-26 | 2005-12-15 | Stratagene California | COMPOSITIONS AND METHODS FOR SYNTHESIZING cDNA |
US20060281109A1 (en) | 2005-05-10 | 2006-12-14 | Barr Ost Tobias W | Polymerases |
US20070190538A1 (en) | 2005-07-29 | 2007-08-16 | Applera Corporation | Chimeric polymerases |
Non-Patent Citations (43)
Title |
---|
ABRAMSON; MYERS, CURRENT OPINION IN BIOTECHNOLOGY, vol. 4, 1993, pages 41 - 47 |
ALTSCHUL ET AL., METHODS IN ENZYMOLOGY, vol. 266, 1996, pages 460 - 480 |
BOHLKE ET AL., NUCL. ACIDS RES., vol. 28, no. 20, 2000, pages 3910 - 3917 |
BRUTLAG, D.; KORNBERG, A., J. BIOL. CHEM., vol. 247, 1972, pages 241 - 248 |
CHANG, L. M. S., J. BIOL. CHEM., vol. 252, 1977, pages 1873 - 1880 |
CLINE, J. ET AL., NAR, vol. 24, 1996, pages 3546 - 3551 |
ERLICH, REV IMMUNOGENET., vol. 1, 1999, pages 127 - 34 |
FOGG ET AL., NATURE STRUCTURAL BIOLOGY, vol. 9, no. 12, 2002, pages 922 - 927 |
GUAGLIARDI ET AL., J. MOL. BIOL., vol. 267, 1997, pages 841 - 848 |
H. A. ERLICH: "PCR Technology : Principals and Applications for DNA Amplification", 1989, STOCKTON PRESS |
HAMILTON ET AL., BIOTECHNIQUES, vol. 31, 2001, pages 370 - 383 |
HASHIMOTO ET AL., J. MOL. BIOL., vol. 306, no. 3, 2001, pages 469 - 477 |
HOPFNER ET AL., PROC. NATL. ACAD. SCI., vol. 96, no. 7, 1999, pages 3600 - 3605 |
INNIS ET AL.: "PCR Protocols: A Guide to Methods and Applications", 1990, ACADEMIC PRESS |
JURECIC ET AL., CURR. OPIN. MICROBIOL., vol. 3, 2000, pages 316 - 21 |
KIM ET AL., INT. J. BIOL. MACROMOL., vol. 42, no. 4, 2008, pages 356 - 61 |
KONG ET AL., J. BIOL. CHEM., vol. 268, 1993, pages 1965 |
KONG ET AL., J. BIOL. CHEM., vol. 268, no. 3, 1993, pages 1965 - 1975 |
KOVAROVA, M.; DRABER, P., NUCL. ACIDS RES., vol. 28, no. 13, 2000, pages E70 |
KOVAROVA; DRABER, NUCL. ACIDS. RES., vol. 28, no. 13, 2000, pages E70 |
KUROITA ET AL., J. MOL. BIOL., vol. 351, 2005, pages 291 - 298 |
LAWYER ET AL., J. BIOL. CHEM., vol. 264, 1989, pages 6427 - 647 |
LAWYER ET AL., PCR METH. & APP., vol. 2, 1993, pages 275 |
LUNDBERG, K. S.; SHOEMAKER, D. D.; ADAMS, M. W. W.; SHORT, J. M.; SORGE, J. A.; MATHUR, E. J., GENE, vol. 180, 1991, pages 1 - 8 |
M. J. MCPHERSON ET AL.: "PCR: A Practical Approach", 1991, IRL PRESS |
MACLELLAND ET AL., PCR METHODS APPL., vol. 4, 1994, pages S66 - 81 |
NUCL. ACIDS RES., vol. 24, no. 18, 1996, pages 3546 - 3551 |
PAVLOV ET AL., PROC NATL ACAD SCI., vol. 99, no. 21, 2002, pages 13510 - 13515 |
PAVLOV ET AL., PROC. NATL. ACAD. SCI., vol. 99, no. 21, 2002, pages 13510 - 13515 |
PREDIGER, METHODS MOL. BIOL., vol. 160, 2001, pages 49 - 63 |
RODRIGUEZ ET AL., J. MOL. BIOL., vol. 299, 2000, pages 447 - 462 |
SAMBROOK ET AL.: "Molecular Cloning second edition,", 1989, COLD SPRING HARBOR LABORATORY PRESS |
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual 3rd ed.,", 2001, COLD SPRING HARBOR LABORATORY PRESS, pages: 9.63 - 9.75 |
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 2001, COLD SPRING HARBOR LABORATORY PRESS |
See also references of EP2352818A4 |
TRIGLIA, METHODS MOL. BIOL., vol. 130, 2000, pages 79 - 83 |
VON HIPPEL ET AL., NYAC,A SCI, vol. 726, 1994, pages 118 - 131 |
VON HIPPEL ET AL., NYACAD SCI, vol. 726, 1994, pages 118 - 131 |
WANG ET AL., CELL, vol. 89, 1997, pages 1087 - 1099 |
WANG ET AL., NUCL ACIDS RES., vol. 32, no. 3, 2004, pages 1197 - 1207 |
WANG ET AL., NUCL. ACIDS RES, vol. 32, no. 3, 2004, pages 1197 - 1207 |
WANG ET AL., NUCL. ACIDS RES., vol. 32, no. 3, 2004, pages 1197 - 1207 |
WATSON, J. D. ET AL.: "Molecular Biology of the Gene, 4th Ed. ,", 1987, W. A. BENJAMIN, INC. |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11603547B2 (en) | 2008-11-03 | 2023-03-14 | Kapa Biosystems, Inc. | Modified type A DNA polymerases |
US10961555B2 (en) | 2008-11-03 | 2021-03-30 | Kapa Biosystems, Inc. | Modified type A DNA polymerases |
US10975361B2 (en) | 2011-01-14 | 2021-04-13 | Kapa Biosystems, Inc. | Modified DNA polymerases for improved amplification |
US11746339B2 (en) | 2011-01-14 | 2023-09-05 | Kapa Biosystems, Inc. | Modified DNA polymerases for improved amplification |
CN102392000A (en) * | 2011-11-07 | 2012-03-28 | 李志茹 | High-temperature-resistant Pyrolobus polymerase and efficient expression plasmid and application thereof |
CN104250641A (en) * | 2013-06-28 | 2014-12-31 | 思洛生物技术股份有限公司 | High fidelity DNA polymerase and preparation and application thereof |
CN104250641B (en) * | 2013-06-28 | 2017-09-01 | 北京福安华生物科技有限公司 | A kind of high-fidelity DNA polymerase and its preparation and application |
US9447445B2 (en) | 2014-08-27 | 2016-09-20 | New England Biolabs, Inc. | Synthon formation |
US9963687B2 (en) | 2014-08-27 | 2018-05-08 | New England Biolabs, Inc. | Fusion polymerase and method for using the same |
EP3450558A3 (en) * | 2014-08-27 | 2019-05-15 | New England Biolabs, Inc. | Synthon formation |
WO2016033315A3 (en) * | 2014-08-27 | 2016-06-02 | New England Biolabs, Inc. | Synthon formation |
EP3778891A1 (en) * | 2014-08-27 | 2021-02-17 | New England Biolabs, Inc. | Synthon formation |
CN108064278A (en) * | 2014-11-14 | 2018-05-22 | 亿明达股份有限公司 | Polymerase |
US10329545B2 (en) | 2014-11-14 | 2019-06-25 | Illumina, Inc. | Polymerases |
EP3218471A1 (en) * | 2014-11-14 | 2017-09-20 | Illumina, Inc. | Polymerases |
CN108064278B (en) * | 2014-11-14 | 2022-02-08 | 亿明达股份有限公司 | Polymerase enzyme |
US10995324B2 (en) | 2014-11-14 | 2021-05-04 | Illumina, Inc. | Polymerases |
WO2016077795A1 (en) * | 2014-11-14 | 2016-05-19 | Illumina, Inc. | Polymerases |
US10858652B2 (en) | 2016-01-19 | 2020-12-08 | Board Of Regents, The University Of Texas System | Thermostable reverse transcriptase |
EP4067491A1 (en) * | 2016-01-19 | 2022-10-05 | Board of Regents, The University of Texas System | Thermostable reverse transcriptase |
EP3405578A4 (en) * | 2016-01-19 | 2019-09-25 | Board of Regents, The University of Texas System | Thermostable reverse transcriptase |
WO2017127510A2 (en) | 2016-01-19 | 2017-07-27 | Board Of Regents, The University Of Texas System | Thermostable reverse transcriptase |
US11912991B2 (en) | 2016-01-19 | 2024-02-27 | Board Of Regents, The University Of Texas System | Thermostable reverse transcriptase |
US11312944B2 (en) | 2016-12-19 | 2022-04-26 | Quantum-Si Incorporated | Polymerizing enzymes for sequencing reactions |
US11866785B2 (en) | 2017-10-27 | 2024-01-09 | Board Of Regents, The University Of Texas System | Tumor specific antibodies and T-cell receptors and methods of identifying the same |
GB2587177A (en) * | 2019-01-09 | 2021-03-24 | 3Cr Bioscience Ltd | Polymerase |
WO2020144480A1 (en) * | 2019-01-09 | 2020-07-16 | 3Cr Bioscience Ltd. | Method for detecting a nucleic acid sequence |
US11959105B2 (en) | 2019-06-28 | 2024-04-16 | Quantum-Si Incorporated | Polymerizing enzymes for sequencing reactions |
Also Published As
Publication number | Publication date |
---|---|
JP6150847B2 (en) | 2017-06-21 |
EP2927317A1 (en) | 2015-10-07 |
WO2010062776A3 (en) | 2010-08-19 |
EP2352818A4 (en) | 2011-10-12 |
CA2742593C (en) | 2020-05-05 |
HK1216032A1 (en) | 2016-10-07 |
US20120115188A1 (en) | 2012-05-10 |
JP2012507986A (en) | 2012-04-05 |
CN102257136A (en) | 2011-11-23 |
EP2927317B1 (en) | 2018-12-19 |
ES2571446T3 (en) | 2016-05-25 |
ES2716402T3 (en) | 2019-06-12 |
US20140363848A1 (en) | 2014-12-11 |
JP2015154787A (en) | 2015-08-27 |
JP2017029172A (en) | 2017-02-09 |
EP2352818A2 (en) | 2011-08-10 |
US9388396B2 (en) | 2016-07-12 |
CA2742593A1 (en) | 2010-06-03 |
US9023633B2 (en) | 2015-05-05 |
EP2352818B1 (en) | 2016-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9388396B2 (en) | Chimeric DNA polymerases | |
US8481685B2 (en) | Modified DNA polymerases | |
CA2498764C (en) | Helicase dependent amplification of nucleic acids | |
US5541099A (en) | Cloning and expression of T5 DNA polymerase reduced in 3'-to-5' exonuclease activity | |
DK2079834T3 (en) | Mutant DNA polymerases and related methods | |
US5939301A (en) | Cloned DNA polymerases from Thermotoga neapolitana and mutants thereof | |
AU658378B2 (en) | Purified thermostable nucleic acid polymerase enzyme from thermosipho africanus | |
CN107475216B (en) | Recombinant heat-resistant DNA polymerase and application thereof | |
AU2001271270A1 (en) | Thermostable reverse transcriptases and uses thereof | |
CN109749976B (en) | Recombinant bacillus subtilis for efficiently synthesizing guanosine diphosphate fucose and construction method and application thereof | |
NO323846B1 (en) | Purified thermostable DNA polymerase from Carboxydothermus hydrogenoformans, isolated DNA sequence encoding it, vector containing the sequence, microbial host comprising the vector, DNA polymerase preparation method, DNA amplification method, DNA cloning and DNA sequencing, DNA labeling and reverse transcription using the polymerase. | |
CN107699535B (en) | Recombinant bacillus subtilis for induced synthesis of guanosine diphosphate fucose and construction method and application thereof | |
EP1012161B1 (en) | High fidelity polymerases and uses thereof | |
CN113862264A (en) | Adapters, constructs, methods and uses for sequencing of target polynucleotides | |
Oscorbin et al. | Bst polymerase—a humble relative of Taq polymerase | |
WO2003048310A2 (en) | Thermus oshimai nucleic acid polymerases | |
Keith | Investigating thermostable DNA polymerases for PCR-based applications | |
AU2005234731A1 (en) | High fidelity reverse transcriptases and uses thereof: RSV and AMV |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980151063.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09829689 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011534889 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2742593 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009829689 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3769/DELNP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13127420 Country of ref document: US |